

Division of Health Care Finance
Landon State Office Building
900 SW Jackson, Suite 900 N
Topeka, Kansas 66612-1220



Phone: 785-296-3981
Fax: 785-296-4813
www.kdheks.gov

Lee A. Norman, M.D., Secretary

Laura Kelly, Governor

**Drug Utilization Review Board Meeting
Agenda, Open Session July 21, 2021
10:00 a.m. – 2:00 p.m.**

Meeting Location*

*Due to COVID-19, this meeting will be held virtually. Please use the information below to join the meeting:

Public/Participant Line: Dial: (312) 626-6799, Meeting ID: 871 4397 3724

Zoom Meeting: <https://us02web.zoom.us/j/87143973724>, Passcode: 254284

Members of the general public are required to complete a conflict of interest form if they intend to provide public comments to the Board. To assist the operator in coordinating public comment, completed forms are due 1 week prior to the meeting (July 14, 2021). Please email the completed form to Annette.Grant@ks.gov.

Board Members

Moneeshindra Mittal, MD
James Backes, PharmD
Jennifer Clair, MD
Gregory Burger, PharmD, CPPS, FASHP, EMT

Michele Reisinger, DNP, APRN, FNP-BC
Arthur Snow, MD
Kristen Powell, PharmD

KDHE-DHCF Staff

Annette Grant, RPh
Victor Nguyen, PharmD

Carol Arace, Administrative Specialist

Gainwell Technologies/KEPRO Staff

Karen Kluczykowski, RPh
Kathy Kaesewurm, RN, BSN

Christina Faulkner, PharmD, BCPS
Harry Vu, PharmD

MCO Staff

Mark DeMary, PharmD, **Aetna Better Health of Kansas**
Angie Yoo, PharmD, **Sunflower State Health Plan**
Sunny Bounyalath, PharmD, **UnitedHealthcare Community Plan**

I. CALL TO ORDER

A. Announcements

This meeting will be operator-assisted. An opportunity for public comment was given at the top of the agenda.

II. OLD BUSINESS

A. Review and Approval of April 21, 2021 Meeting Minutes

III. NEW BUSINESS

A. Mental Health Medication Advisory Committee (MHMAC)

1. ADHD Medications – Safe Use for All Ages

At the May 2021 MHMAC meeting, the committee revised the ADHD Medications – Safe Use for All Ages criteria to include Evekeo® ODT, Qelbree®, and Azstarys™ and updates to the dosing limits table. Step therapy for Qelbree® was also reviewed.

- i. Prior Authorization Criteria
- ii. *Public Comment
- iii. Board Discussion

2. Antidepressant Medications – Safe Use for All Ages

At the May 2021 MHMAC meeting, the committee revised the Antidepressant Medications – Safe Use for All Ages criteria to reflect Spravato® labeling updates.

- i. Prior Authorization Criteria
- ii. *Public Comment
- iii. Board Discussion

3. Antipsychotic Medications – Safe Use for All Ages

At the May 2021 MHMAC meeting, the committee revised the Antipsychotic Medications – Safe Use for All Ages criteria to include step therapy requirements for Secuado®.

- i. Prior Authorization Criteria
- ii. *Public Comment
- iii. Board Discussion

B. Revised Prior Authorization (PA) Criteria

1. Crohn's Disease Agents

This revision updates requirements for renewal prior authorization requests. It also updates requirements for Tysabri®.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

2. Oncology Agents

This revision includes the addition of several drugs to the list of agents requiring prior authorization.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

3. Oncology – Auxiliary Treatment Agents

This revision includes the addition of several drugs and consolidation of existing criteria (Anti-emetics: Neurokinin 1 (NK-1) Antagonists/NK-1 Antagonist Combinations).

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

4. Migraine Prophylaxis Agents

This revision includes the addition of Nurtec® ODT and adds step therapy.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

5. Weight Loss Agents

This revision includes addition of Wegovy™ and revises the initial and renewal criteria for all agents.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

6. Ulcerative Colitis (UC) Agents

This revision includes addition of Zeposia® to the list of agents requiring prior authorization and includes dosing information and renewal criteria.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

7. Minimum Requirements Prior Authorization

This revision reflects an update to the age indication for Trikafta® use.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

8. Opioid Products Indicated for Pain Management

This revision includes the addition of Qdolo™ and finalization of a minor clarification regarding approval duration.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

9. Atopic Dermatitis Agents

This revision includes updates to the initial and renewal criteria.

- i. Revised PA Criteria
- ii. *Public Comment
- iii. Board Discussion

IV. APPOINTMENT OF CHAIRPERSON AND INTERIM CHAIRPERSON

V. ADJOURN

The next DUR Board meeting is scheduled for October 20, 2021.

*Public comment is limited to five minutes per product; additional time will be allowed at the DUR Board's discretion.

****THIS AGENDA IS SUBJECT TO CHANGE****